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Background: Patients undergoing bronchoscopy are usually monitored only by pulse oximetry,
hence hypoventilation cannot be assessed. Transcutaneous carbon dioxide tension (TcPCO2 )
monitoring is a non-invasive technique to assess hypoventilation. Patients with severe chronic
obstructive pulmonary disease (COPD) undergoing bronchoscopy are at increased risk for seda-
tion-induced hypoventilation. The aim of the study was to measure TcPCO2 using a digital
sensor to examine the occurrence of hypoventilation during bronchoscopic lung volume reduc-
tion (BLVR).
Methods: Combined TcPCO2 and SpO2 saturation and arterial blood gases (ABG) were prospec-
tively measured in 15 patients with severe COPD (Mean FEV1 29%) undergoing BLVR under
conscious sedation with IV midazolam and IV alfentanil.
Results: A highly significant correlation was noted between simultaneous ABG PCO2 samplings
and TcPCO2 measured (RZ 0.85, p < 0.001). Mean baseline TcPCO2 level was 41.7  10.3 mm
Hg (SD) (range 35e66 mmHg)], and peak measurement during the procedure was
61  17.1 mm Hg (range 41e111 mmHg). The mean increase in TcPCO2 during bronchoscopy
was 19.2 (range 3.7e45 mmHg) [p < 0.0001]. Mean duration of significant hypercapnea
(TcPCO2 > 55 mmHg), observed in 7 (46%) patients, was 9 min (range 0e53).
Conclusions: Bronchoscopy performed under conscious sedation in patients with severe COPD
is frequently associated with significant hypoventilation that can only be detected by TcPCO2s carbon dioxide tension; COPD, chronic obstructive pulmonary disease; BLVR, bronchoscopic lung
gases; TLC, total lung capacity; RV, residual volume.
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Transcutaneous CO2 during BLVR 603monitoring. Combined measurement of SpO2 and TcPCO2 during bronchoscopy enhances
patient safety, helps guide administration of sedation, and can alert physicians to the need
for anesthesia reversal following completion of bronchoscopic interventions.
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Bronchoscopy is often performed using sedation.1,2 As drug-
induced respiratory depression is a major cause of seda-
tion-associated morbidity during bronchoscopy, pulse oxi-
metry has been established as standard practice to detect
hypoxemia.3 However, oxygen saturation (SpO2) measured
with pulse oximetry does not reflect ventilation.4 Because
supplemental oxygen is commonly used during bronchos-
copy, this can mask hypoxemia associated with hypo-
ventilation that might otherwise be detected through pulse
oximetry. Intermittent or continuous samplings of arterial
blood are invasive and expensive procedures, and are
therefore not used in this setting. In addition, the delay in
obtaining results is a major drawback of arterial blood gas
sampling, making it impractical for use as monitoring aid
during bronchoscopy.
Capnography represents an alternate monitoring
approach, which is non-invasive and straightforward.6e8
However, Capnography is difficult to perform in patients
undergoing FB under conscious sedation, and is not accu-
rate in patients with severe COPD.9
Intermittent or continuous monitoring of transcutaneous
PaCO2 (TcPCO2), provides a real time assessment of venti-
latory status that is simple to implement and well-tolerated
by patients. However few studies have examined the value
of measuring TcPCO2 during FB using a sensitive digital
sensor.10e12 Patients with severe chronic obstructive
pulmonary disease (COPD) are particularly prone to develop
hypoxemia and hypercapnea during sedation13 and hence
represent an ideal study population for evaluating the value
of TcPCO2 monitoring during bronchoscopy.
The purpose of this study was to examine in a group of
patients with advanced COPD (heterogeneous and homo-
egenous disease) trends in TcPCO2 measurements during
a particular FB procedure: polymeric lung volume reduction
(PLVR) performed under conscious sedation. PLVR is a new
investigational endobronchial procedure for treating hyper-
inflation in advanced emphysema designed to directly
reduce lung volume by collapsing and sealing damaged areas
of hyperinflated lung in patients with emphysema.14e16Materials and methods
Patients population
All study participants had severe airflow obstruction,
emphysema and respiratory symptoms despite medical
therapy. Specific study inclusion criteria included: 1.
Homogeneous or heterogeneous emphysema determined by
high resolution computed tomography (CT) imaging; 2.
Persistent symptoms with GOLD stage III-IV obstructive lung
disease (i.e. a baseline Medical Research Council Dyspnoea(MRCD) score of 2) despite medical therapy; 3. Severe
airflow limitation, defined as a ratio of FEV1 to forced
vital capacity (FVC) < 70% and an FEV1< 45% of predicted;
4. Hyperinflation (total lung capacity (TLC) > 110% pre-
dicted and residual volume (RV) > 150% of predicted);
5. Abstinence from smoking for  4 months prior to
enrolment.
All patients signed an informed consent to participate in
the trial which was approved by the Local Ethics Committee.
The PLVR procedure
PLVR therapy is a new synthetic tissue sealant made of liquid
foam prepared at bedside that polymerizes in situ. It is
delivered via catheter to the lung subsegment with the
bronchoscope in wedge position. The material flows as
a liquid into the alveolar compartmentwhere it polymerizes,
adheres and causes absorption atelectasis. Patients are
prepared for the procedure as follows. The patient is placed
in the supine position for FB. Nasal oxygen is administered at
2e4 L/min. Patients receive topical anesthesia with lido-
caine, IV alfentanil, 0.5 mg, and intermittent boluses of IV
midazolam. No other sedating or hypnotic agents were used
in this study. The fiberoptic bronchoscope (BF-1T240 Video
Bronchoscope; Olympus Corporation, Tokyo, Japan, or Pen-
tax FB-18X Fiber Bronchoscope, Pentax, Tokyo, Japan) was
introduced transnasally and advanced to target sub-
segmental bronchi. 20 ml of the polymeric sealant was
injected through a catheter to the target segmental bronchi.
Two (2) subsegments were treated during each procedure.
Each treatment requires 3e4 min to complete, and total
procedure times, from the time of bronchoscope insertion to
removal were 3.5  0.7 min (range 3.2e7.1 min).
TcPCO2 monitoring
For thevalidationpartof thestudy, all earlobePcCO2andSpO2
readingswere comparedwithPaCO2 and SaO2 values obtained
simultaneously by arterial puncture (average of blood gas
analyzers ABL 500 and ABL 725, Radiometer, Copenhagen,
Denmark). A combined digital earlobe sensor (Sentec AG;
Therwil, Switzerland) measuring SpO2 (percentage) and
PcCO2 (millimeters ofmercury) was used to obtain continuous
values that were logged on a computer. Baseline PcCO2 was
registered once steady state was achieved. This device
measures the PcCO2 using a Severinghaus-type electro-
chemical sensor, and the SpO2 and pulse rate are measured
using conventional optical SpO2 sensors.
Statistical analysis
Descriptive data are presented as mean (SD). Compari-
sons between baseline values and values obtained during
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continuous variables). Correlation between measurements
was made by the Pearson correlation coefficient. Two-sided
p value of <0.05 was considered to be statistically signifi-
cant. All of the statistical analyses were performed using
a statistical software package (MedCalc Version 9.3.0.0,
USA).
Results
The demographic and clinical details of the patients are
shown in Table 1. TcPCO2 was prospectively measured in 15
consecutive patients (11 men and 4 women; mean age
65.1  6.4 yr (SD) Range: 54e76 years) with severe COPD
(Mean FEV1 29.3  8.0% of predicted, Mean FEV1/FVC ratio:
0.69) undergoing PLVR. Patients had significant air-trapping
(mean residual volume/total lung capacity ratio:
172.5%  15.7 of predicted), and low diffusion capacity
measured by the single breath CO method (52.7%  12.3 of
predicted).
Mean duration of the procedure from sedation onset to
recovery was 36  31 min (range 6e75 min). There were no
complications during the procedure. The mean dosages
administered for midazolam and alfentanil were
4.2  1.2 mg (range, 3e7 mg) and 0.6  0.2 mg (range,
0.5e1 mg), respectively.
Correlation between simultaneous arterial blood gas
samplings and transcutaneous measured carbon dioxide
tension and oxygen saturation were excellent over a wide
range of PaCO2 and SpO2. The Pearson correlation coeffi-
cients were R Z 0.8552 and R Z 0.7934, respectively (See
Fig. 1).
Mean baseline TcPCO2 level was 41.7  10.3 mm Hg
(SD) [range 35e66 mm Hg], and peak measurement during
the procedure was 61  17.1 mm Hg (range 41e111 mmHg)
[p < 0.001]. No significant difference was noted betweenTable 1 Demographic and clinical characteristics of study pat
bronchoscopic lung volume reduction.
Characteristics Age (yr) Gender FEV1 (%) FEV1/
#1 58 f 24 0.48
#2 59 m 29 0.46
#3 72 m 36 0.42
#4 70 m 28 0.40
#5 70 m 29 0.40
#6 65 F 36 0.41
#7 66 F 36 0.43
#8 66 f 48 0.42
#9 64 m 26 0.37
#10 66 m 34 0.56
#11 66 m 34 0.56
#12 70 m 21 0.41
#13 76 m 22 0.31
#14 53 m 19 0.37
#15 54 m 17 0.33
Mean (± SD) 65.1 (6.4) 29.3 (8) 0.42baseline PCO2 following sedation and following insertion of
the bronchoscope (probably due to the fact that the time
period between these two events was negligible). The
PcCO2 showed an increase in all patients during the
procedure. Mean change in TcPCO2 measurement from
baseline to mean level during the procedure was
8.1  5.4 mm Hg [p Z 0.0029]. The mean difference
between baseline TcPCO2 and peak level during the
procedure was (SD) 19.2  11.9 mmHg, range
3.7e45 mmHg. A representative course of SaO2 and TcPCO2
recording in a COPD patient during BLVR under conscious
sedation is presented in Fig. 2.
A total of 9 patients (60%) developed a rise in TcPCO2 of
more than 15 mmHg during the procedure. Mean duration of
significant hypercapnea (PCO2 > 55 mmHg) was 9 min
(range 0e22 min) and it was observed in 7 patients (46%).
The mean baseline SpO2 on room air was 89.9  3.7%
(range, 85e95%), and the lowest during the procedure was
85.9  5.9% (range, 70e93%). Mean duration of significant
hypoxemia (SpO2 < 88%) during the procedure was 0.8 min
(range 0e4.3 min). Significant hypoxemia was detected in
10 (67%) of patients. A significant correlation was noted
between baseline TcPCO2 level and peak TcPCO2 during the
procedure (Correlation coefficient R Z 0.7247;
PZ 0.0022). Baseline spirometric data (FEV1, RV/TLC ratio
or diffusion capacity) did correlate significantly with
development of significant hypercapnea during the bron-
choscopic procedure.
The mean TcPCO2 at the end of the procedure was
36.9 mmHg. Only three patients received reversal therapy
(2 with flumazenil and 1 with narcan) for hypercapnea at
the end of the procedure (patients # 3, #13 and # 14.). One
patient required short term invasive ventilatory support for
hypercapnea upon completion of therapy (patient # 10),
hypercapnea resolved rapidly over 30 min, leading to
subsequent extubation.ients and monitoring data obtained before, during and after
FVC RV/TLC Procedure
length (min)
TcPCO2 baseline
before sedation
(mmHg)
200 26 36.1
173 31 37
153 24 35.2
172 14 40.3
174 32 39.2
185 23 35.7
187 32 36.1
148 58 27
175 6 27.1
153 23 43.2
150 36 42.1
172 32 33.2
167 140 64.3
190 58 56.1
192 15 42.3
(0.06) 172.5 (15.7) 36.6 (31.9) 39.6 (9.7)
Figure 1 Correlation between baseline transcutaneous PCO2 measured with the combined earlobe sensor and simultaneously
arterially measured PCO2 in 15 study patients..
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Novel bronchoscopic procedures are being developed to
replace interventions that previously required major
thoracic surgery. As these procedures become more
complex, and the target patient population becomes sicker,
a need for more intensive procedural monitoring has
evolved. Use of sedative medications predispose toTcPCO2
following
sedation
(mmHg)
TcPCO2
baseline during
bronchoscopy
(mmHg)
TcPCO2 peak
during
procedure
(mmHg)
Increase in
TcPCO2 from
baseline
(mmHg
37.7 38.7 48 9.3
38.1 38.3 57 18.7
35.1 36.5 54 17.5
41.2 42 52 10
40 41 65 24
36.8 37 48 11
36.5 36.3 70 33.7
27.5 28 68 40
28.1 29.3 41 11.7
45.2 46.3 65 18.7
43.1 44.7 54 9.3
34.2 35.8 55 19.2
65.3 66 111 45
60.1 61.4 78 16.6
44.3 45.3 49 3.7
40.8 (10.2) 41.7(10.3) 61.0(17.1) 19.2(11.9)hypoventilation that can result in clinically significant
hypercapnea. This is particularly the case in patients with
advanced underlying lung disease. Data presented here
indicate that patients with severe COPD undergoing ther-
apeutic bronchoscopic interventions such as PLVR under
conscious sedation can experience significant hypercapnea
and hypoxemia, and that continuous measures of SpO2 and
TcPCO2 can help guide patient management.TcPCO2 at the
end of the
procedure
(mmHg)
Time TcPCO2>
55 mmHg (min)
SO2
baseline%
Time SO2<
88% (min)
38.2 0 94 0.0
37 18.4 91 0.0
49 0 91 0.1
35.1 0 88 0.0
32 7 86 0.9
37 0 91 0.8
43 9 87 0.1
31 5.36 95 4.4
34 0 93 0.0
68 7.28 85 0.1
41 0 85 2.0
42 3.2 94 0.1
65 32 88 0.0
63 53 86 2.3
30 0 95 1.3
36.9(5.1) 9.0 (15.9) 89.9(3.7) 0.8 (1.2)
Figure 2 Typical course of SaO2 (lower part) and TcPCO2 (upper part) recording in a 53 year old patient (Pt. # 14) with severe
COPD (FEV1 18% of predicted) during BLVR under conscious sedation (IV midazolam 3 mg and IV alfentanil 0.5 mg) demonstrating an
increase in TcPCO2 of 16.6 mmHg up to a level of 78 mmHg that reflects sedation-induced hypoventilation.
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documented a statistically significant increase in TcPCO2
from mean stable baseline levels of 43.5 mm Hg (range
31.5e59.2 mmHg) to mean peak levels during bronchoscopy
of 52.5 mmHg (range 37.5e65.2 mmHg). The mean peak
level in our study cohort (61 mmHg) is considerably higher
than that observed in Evans et al., trial. This difference
may be due to inclusion of only patients with advanced
COPD in our current study whereas the population in the
previous trial included patients with less severe lung
disease.
Our results indicate that patients with severe COPD are
indeed prone to sedation-induced hypoventilation, and that
continuous monitoring of both SpO2 and PcCO2 during
procedures such as PLVR may increase the safety during the
procedure. The findings of the present study add data to
a previous report by Chhajed et al.,11 that patients with
COPD who do not have chronic hypercapnea are neverthe-
less at risk of hypercapnea and hypoxemia during sedation
for bronchoscopic procedures. Our results confirm this in an
overall sicker patient population. Chhajed et al.,11 sug-
gested that a rise of 15 mmHg from baseline may be an
indication to limit further administration of sedatives. In
our population of severe COPD patients although baseline
hypercapnea was significantly associated with peak TcPCO2
during the procedure, out of nine patients that had a rise of
TcPCO2 of more than 15 mmHg, only 3 (33%) had baseline
hypercapnea (defined as PCO2 > 45 mmHg) No significant
difference was noted between the dosage of midazolam or
alfentanil used in patients that developed significant
hypercapnea and those that did not. Johnson et al.,12 used
TcPCO2 monitoring during bronchocopies on ventilated
patients. TcPCO2 rose by a mean of 10.7 mmHg in those
patients, with ventilator settings changed in nearly half the
bronchoscopies because of this rise in TcPCO2.
Our results show that clinically significant hypo-
ventilation occurs frequently in patients with severe COPD
undergoing bronchoscopic procedures such as PLVR, andthat the risk of hypercapnea cannot be readily predicted
from baseline characteristics or sedation drug dosage. With
the common practice of supplemental oxygen usage to
prevent hypoxemia, the measurement of carbon dioxide
tension adds additional important information because
hypoventilation is not reflected by pulse oximetry.5,6
TcPCO2 monitoring enabled us to identify clinically signifi-
cant hypoventilation and institute appropriate therapy,
including restriction of further sedation, use of reversal
drugs, and/or use of upper airway support in a timely
fashion.17,18 Another option would be the use of non-inva-
sive ventilatory support by Bi-level non-invasive ventilation
both during and following the procedure.
In summary, bronchoscopic procedures for patients with
severe COPD performed under conscious sedation can be
associated with significant hypoventilation. Combined
measurements of SpO2 and TcPCO2 enhance patient safety
during bronchoscopic procedures, and guide sedation
administration.
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